Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could an iPhone app help beat eating disorders?

NCT ID NCT06226233

Symptom relief Sponsor: King's College London Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether a digital self-help app called Juniver can reduce symptoms of eating disorders like anorexia, bulimia, and binge eating. 300 adults in the UK and US will use the app for 12 weeks and report their symptoms. The app includes therapy-based lessons, interactive tools, and peer support groups.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Juniver program (digital self-help app)
What this could lead to
If it works, this could provide a widely accessible, low-cost digital tool to help people manage eating disorder symptoms from home.
What could go wrong
This is an early-stage trial with no blinding or placebo control, and results rely on self-reported symptoms. The app may not work for severe cases or those without an iPhone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2023

Expected to finish

Aug 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 16 or over * Live in the UK or the US * Any presence and severity of any eating disorder(s): Anorexia Nervosa, Bulimia Nervosa, Binge Eating Disorder, Other Specified Feeding and Eating Disorders (OSFED), Avoidant Restrictive Food Intake Disorder (ARFID) and Unspecified Feeding or Eating Disorder (UFED) as measured by the EDE-Q and using item-based algorithms to determine the potential presence of one of these eating disorders * Able to provide informed consent * Willing to provide full contact details including a UK or US address, phone number and email address * Willing to provide contact details for a health care professional with whom they are registered (e.g., a general practitioner or primary care physician) and who the study team can contact if they are concerned about their well-being. Exclusion Criteria: * Lack of access to an iPhone - as Juniver is currently only available for use on the iPhone system. * Partaking in any medically-driven special diets (e.g., linked to Coeliac, Crohn's, PCOS, type 1 or type 2 diabetes) - as these individuals would require more specialist dietary advice than the Juniver program can safely provide. Individuals with these conditions who are not on special diets would be eligible to enrol. * Severe depression as measured by PHQ score \> 20 * Active suicidal intent or plan .- Body Mass Index (BMI) \<15 * Emergency hospital visit or admission within the last month for an eating disorder or other mental health concern

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anorexia nervosa are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anorexia nervosa avoidant/restrictive food intake disorder binge eating disorder Binge-Eating Disorder bulimia nervosa eating disorder Feeding and Eating Disorders Psychological Well-Being

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anorexia nervosa Binge eating Binge-eating disorder Bulimia nervosa Disordered eating Eating disorders Feeding and eating disorders

Contacts and locations

Locations

  • King's College London

    London, London, SE5 8AZ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.